Skip to main content
All lobbying filings

ALSTON & BIRD LLP

Lobbying for BIOMERIEUX, INC. · Global in vitro diagnostics company.

 Filing Registration
2nd Quarter (Apr 1 - June 30) 2025 · Utah · posted Jul 21, 2025

Official filing document

 Bills named in this filing 1
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
 Lobbying activity 5
Budget/Appropriations

H.R.1, the One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)). Discussions regarding tariff proposals.

Health Issues

H.R.1, the One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)). Discussions regarding tariff proposals.

Medical/Disease Research/Clinical Labs

H.R.1, the One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)). Discussions regarding tariff proposals.

Medicare/Medicaid

H.R.1, the One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)). Discussions regarding tariff proposals.

Trade (domestic/foreign)

H.R.1, the One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)). Discussions regarding tariff proposals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem